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Introduction
The sentinel lymph node (SLN) refers to the first lymph node 
susceptible to being affected, due to the lymphatic drainage of a 
primary tumor.1 Initially, it was implanted for penile cancer2 followed 
by melanoma and breast cancer.3 The lymph node involvement in 
cancer patients is one of the main prognostic factors.
Regarding pelvic gynecological tumors, the first cancer in which it 
began to be implemented was for the vulva and has spread to cervical 
or endometrial cancer. Knowing the affectation or no ganglion besides 
not only will mark the prognosis4 determines, but also the adjuvant 
treatment in these patients. In addition, selective SLN biopsy is 
considered the strongest predictor of distant metastasis, particularly 
when its affectation is evaluated by immunohistochemistry with 
antibodies against the factor VIII or CD31-related antigen.5 Thanks 
to this, we will be in the habit of carrying out an adequate therapeutic 
strategy.
The implementation of SLN biopsy has among its objectives 
the reduction of morbidity associated with lymphadenectomy,6 
the reduction of surgical time, the reduction of intraoperative7 and 
postoperative complications, such as lymphedema or neuralgia,8 as 
well as reducing the costs associated with conventional surgery. All 
this must be done without entailing a worsening of the prognosis of 
the target disease.
Although this technique has been accepted as an alternative to 
pelvic and para-aortic lymphadenectomy,9,10 it can be difficult to 
expose and understand by our patients, especially in cases in which 
it is associated with an increased risk of recurrence.11 Perhaps these 
patients are not willing to assume a higher risk at the expense of 
reducing the radicality of surgery, something that physicians are. It is 
a challenge on the part of the different specialists, to try to improve 
the results so that SLN does not reduce the treatment of oncological 
patients. For this, it will be essential to make an adequate selection of 
patients. Thus, we will increase our detection capacity in patients with 
early staging and lower tumor sizes.5 Before completely replacing 
the lymphadenectomy, ongoing controlled trials should explore and 
confirm the additional value of SLN biopsy in both perioperative 
morbidity and survival.12 In this review, we intend to perform an 
update on the status of the sentinel node within the current gynecology.
Indications
In order to a certain tumor to be susceptible to SLN biopsy, it must 
follow a consecutive lymphatic drainage through a certain lymph node 
chain. In addition, there must be absence of disease at a distance and 
lymph node involvement both at the clinical level and in the imaging 
tests.13 Also, as a rule the disease should not be locally advanced.
In this way, SLN biopsy, whether by laparoscopy, laparotomy or 
robotic surgery, has proven to be feasible, efficient, safe and imitable.13 
This technique SLN biopsy has been shown to be safe and feasible in 
several gynecological cancers such as vulvar cancer, cervical cancer 
and endometrial cancer.
Detection methods
There are different tracers used for the detection of SLN. Among 
them is technetium 99 (Tc99) or methylene blue (MB), with a 
detection of 66% to 86%. The most recent appearance is the use of 
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Summary
The sentinel lymph node (SLN) refers to the first lymph node susceptible to being 
affected, due to the lymphatic drainage of a primary tumor. The lymph node involvement 
in cancer patients is one of the main prognostic factors. Without affecting the prognosis 
at any time, the SLN seeks to reduce the morbidity associated with lymphadenectomy, 
reducing surgical time, reducing intraoperative and postoperative complications, such 
as lymphedema or neuralgia and costs associated with conventional surgery. Although 
its use has extensive experience in tumors such as breast, the SG in gynecological 
tumors is still in the early stages. With this review we intend to make a close and 
current view of the use of this technique in malignant tumors of the female genital 
tract.
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fluorescent matrices such as indocyanine green (ICG), whose use is 
increasing within the different protocols.14 ICG together with the near 
infrared fluorescence has gained a great utility with the advantage of 
providing real-time images during surgery. It is experimental, the use 
of carbon nanoparticles for labeling remains.15
The superiority of MB has been shown together with the tracer 
versus MB only.16,17 However, ICG has shown greater detection 
capacity than MB and Tc99m.18 In this prospective study by Holloway 
et al.,19 the ICG detected more SLN and more metastases than the MB 
and without safety problems.19 ICG has an excellent toxicity profile, 
with higher overall and bilateral detection rates compared to MB and 
higher bilateral detection rates compared to a combination of Tc-99m 
and blue dye.20,21 There are available studies that even underestimate 
the use of MB in favor of Tc99 or ICG.22 Given this, whenever 
possible, the use of ICG should be favored over the other tracers for 
SLN biopsy.23
One of the variables to consider, is the time elapsed from the 
injection of the tracer until its detection. This period is related to the 
possible failure of intraoperative detection. Kushner et al. reported 
that the best time to detect sentinel lymph nodes with the MB was 
30 minutes after the dye injection. 50 minutes after the injection the 
ICG could not be identified.24 On the other hand, the ICG presents a 
good detection, from 5 to 60 minutes after its injection.25 Taking into 
consideration the time in which the ICG should be detected, its real-
time detection achieves better results with a higher bilateral detection 
rate.26 In addition to the time elapsed, it is important to perform 
the injection of the tracer properly. There are different modalities 
depending on the type of tumor.27,28
 In addition to those mentioned, there are other factors that may 
affect the detection rate of the SLN and should be considered within 
the next protocols and studies. Among them and to highlight, the 
detrimental effect of body mass index (BMI) on ICG detection rates 
as a marker in obese patients.29
Vulva   
An adequate diagnostic and therapeutic strategy in the approach to 
vulvar cancer is essential due to survival is better when the treatment 
is rapidly established after diagnosis. The involvement of the inguinal 
or femoral nodes is the main prognostic factor.30 In this article, we 
review the published data supporting the SLN biopsy as part of the 
standard treatment for women with early-stage vulvar cancer and 
discuss future considerations for the treatment of this disease.31 
Adequate selection of patients with squamous cell carcinoma 
of the vulva is essential.32 The SLN biopsy in vulvar cancer should 
be limited to stages IB and II of the FIGO which they are unifocal 
tumors, less than 4cm and with clinical and radiological absence of 
lymph node involvement. This way, without affecting the prognosis, 
we achieved a reduction in operative mortality.33 In 2008, the first 
Groningen international study on sentinel lymph nodes in vulvar cancer 
(GROINSS-V) demonstrated that the omission of inguino-femoral 
lymphadenectomy is safe in patients with early-stage vulvar cancer 
and negative SLN, simultaneously decreasing morbidity related to the 
treatment. There are sufficient studies that corroborate the viability, 
safety and reproducibility of SLN biopsy in these tumors.34 Some of 
them, such as Slomovitz, show how SLN biopsy is associated with 
a better quality of life than complete lymphadenectomy, is more 
cost-effective than complete lymphadenectomy and achieves a better 
pathological evaluation.32
Something to highlight in the SLN biopsy in vulvar tumors is the 
ultrastaging, since the introduction of this procedure in a standardized 
way, more and lower inguinofemoral ganglion metastases have been 
diagnosed. The true clinical impact of micrometastases is unknown. 
What seems clear is that the larger size of the SLN metastases, make 
greater the chances of metastasis in non-sentinel lymph nodes and 
the lower survival rates. In this way, the size of metastases to the 
lymph nodes is included in the last staging system for vulvar cancer. 
However, micrometastases have not been included in the staging 
of this type of tumors. Further studies are needed to determine the 
clinical consequences of the size of the SLN metastases.35
From a practical point of view, we have extensive experience in 
the use of technetium as a tracer. However, there are already studies 
that have shown that indocyanine green has a similar sensitivity, so it 
should be evaluated in new protocols in order to can incorporate it into 
our usual practice.36
In short, we can see how it has been shown that complete 
inguinofemoral lymphadenectomy is no longer necessary in most 
patients with this disease and there are no excuses for not incorporating 
SLN biopsy in the approach to vulvar cancer. 
Cervix  
Cervical cancer is one of the most frequent gynecological tumors 
in young patients, being one of the main causes of death by this reason 
in developed countries. Frequently, at diagnosis the tumor is limited 
to the cervix, around 47% according to OonK.35 The usual approach 
of these patients goes through radical hysterectomy or trachelectomy 
with bilateral pelvic lymphadenectomy.1,37 This has achieved a high 
survival at 5 years when it comes to early stages.38,39 The SLN biopsy 
is an appropriate option in this type of patients.40
The success of SLN biopsy in cervical cancer will be based on 
an adequate selection of patients in which the tumor is small and is 
treated with low staging. In general, it should be limited to stages 
IA2 and IBI. The best detection rate is found in tumors below 2cm.41 
However, it should be considered that currently, it is an experimental 
technique with a low implantation rate.42
To perform SLN biopsy in cervical cancer, MB can be used with 
or without Tc99. It must be injected into the cervix immediately 
after the anesthesia had been established.41 This can be established 
in each quadrant of the cervix, either at 3 and 9 o’clock in the cervix. 
Intraoperatively, MB an be located at a glance.
There are studies that compare these markers with indocyanine 
green. In patients with early-stage cervical cancer, a higher bilateral 
detection was confirmed using the IG instead of standard techniques.43 
It was also shown in this study by Buda et al. where the conization did 
not have a significant impact on the detection rate of the lymph nodes 
either with MB+Tc99 or with ICG. In the case of advanced cervical 
cancer (stage IB1>2cm), the detection rate was higher with ICG than 
with MB+Tc99.
So that we can see that ICG is a promising tool for SLN in cervical 
cancer, since it seems less affected by the stage of the disease, with a 
higher detection rate compared to traditional methods.42 In addition, 
currently the detection of the sentinel node with GI by means of 
robotics with the da Vinci Xi supposes an added advantage.44
We want to highlight an additional advantage of SLN biopsy in 
cervical cancer. This is the possibility of detecting areas outside of 
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what includes the usual lymphadenectomy, thus being able to have 
additional histological information. On the contrary, there are some 
scenarios that make more studies necessary, such as its application 
in conservative fertility surgery and in patients with neoadjuvant 
chemotherapy.45 In any case, the superiority of SLN biopsy over PET 
in the detection of lymph node disease has been demonstrated.46,47
Although it is a new technique that will require more studies, 
according to the National Comprehensive Cancer Network 
guidelines, the BSGC is a viable option for the management of this 
type of tumors, including it within its therapeutic guidelines.23,30 In 
conclusion, according to the available evidence, the BSCG is a safe 
procedure with high detection rate and low false negative rate.44
Endometrium
Endometrial cancer is the most frequent cancer of the female 
genital tract in the US with 6,180 cases in 2017.36 So, if there is a 
gynecological cancer where the implementation of SLN biopsy is 
most interesting, it is in this tumor. In patients in initial stages, it is 
very important to perform a systematic screening of patients without 
metastasis to lymph nodes to reduce the range of surgical resection, 
and to reduce the incidence of the corresponding complications and 
improve the quality of life of the patients.14 SLN biopsy allows the 
reduction of unnecessary lymphadenectomies and reduces the risk of 
underdiagnosis in patients with metastatic lymph nodes.48 However, 
this technique has the difficulty of the double lymphatic drainage 
pathway of these tumors.49 In addition, the different existing types 
must be considered.50,51 According to the FIRES study, the SLN biopsy 
has a sensitivity of 97.2% and a negative predictive value of 99.6%.51
As in previous cases, several protocols can be used to the SLN 
biopsy in endometrial cancer. Among them, the Tc 99, the MB or 
the ICG. ICG has an excellent toxicity profile, with higher overall 
and bilateral detection rates compared to blue dyes, as well as higher 
bilateral detection rates compared to a combination of Tc-99m and 
MB.26,50,51 The ICG in addition to an excellent detection rate shows 
a low rate of false negatives This superiority has been revealed even 
when we speak of advanced stages (IIIC)51 or high risk types, achieving 
a sensitivity, rate of FN and VPN acceptable. In this way, the SLN 
biopsy with ICG has managed to reduce the total number of complete 
lymphadenectomies, reducing the duration and the additional costs of 
surgical treatment.52–55
The study published by Niikura shows how the tracer injection 
in the cervix is  very sensitive in the detection of SLN metastases in 
early stage endometrial cancer (stages I and II of FIGO). This is a 
particularly useful and safe modality when combined with injection 
of blue dye into the uterine body.56 Controversy exists on the place 
of injection of the tracer. In this regard, the study published by 
Rossi shows how cervical ICG injection achieves a higher rate of 
SLN detection and an anatomical lymph node distribution similar 
to hysteroscopic endometrial injection in patients with endometrial 
cancer.57
In summary, BSCG with GI is a feasible technique with high 
diagnostic precision that could eventually displace conventional 
lymphadenectomy in the coming years, thus reducing the associated 
morbidity and mortality.51
Ovary
There are few studies about SLN biopsy in ovarian cancer. 
Anatomy, various histological types and their drainage, or tracer 
injection, are some of the difficulties that contribute to the limited 
scientific evidence available. An example of this is the study of the 
Buddha where ICG is used for aortic staging in 10 patients with 
ovarian cancer. In 9 cases the SLN was detected in the aortic region 
after the injection of the tracer. In 3 cases, SLN were also identified in 
the common iliac region.58
Costs  
There are few studies that evaluate the costs associated with the use 
of the sentinel lymph node. A sample of this is the study of Buddha, 
who showed that with SLN biopsy in endometrial cancer there is 
a reduction of more than 1000 dollars compared to conventional 
lymphadenectomy. Assuming a total of 66 million dollars less for 
the total cases of ca. Endometrium in the USA. On the other hand, 
when we refer to vulvar cancer, SLN biopsy seems the least expensive 
alternative, mainly due to the great impact of lymphedema associated 
with conventional surgery on quality of life.59 According to the study 
of van der Vorst, with the SLN biopsy in vulvar cancer a reduction 
of 22416 dollars on an annual basis with respect to conventional 
surgery.60
When comparing the use of the different tracers, the option that the 
ICG uses seems to be the most profitable strategy.61,62
Conclusion  
The BSGC in gynecological tumors is a current technique that 
manages to reduce the morbidity and mortality associated with 
traditional surgery, in addition to achieving a reduction in costs 
associated with it. This is also achieved, without interfering in the 
prognosis of these patients. New standardized studies are needed to 
reinforce and homogenize this technique so that we can incorporate it 
into our usual protocols.
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